USNANYSEMedicinal Chemicals & Botanical ProductsFiscal year ends January 3
USANA HEALTH SCIENCES INC
Financials through Q2 FY2026, quarter ended Jul 4, 2026Last filing: 10-Q on Aug 13, 2026
$14.89−0.65 (-4.18%)
Close on Oct 19, 2026
- Market cap
- $275.26M
- P/E (TTM)
- –
- Dividend yield
- –
USANA HEALTH SCIENCES INC revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hiya | $121.36M | $127.03M | $131.97M | – | – | – | – | – | – | – | – | – | 13.3% | – |
| Direct selling | – | – | – | $795.37M | $818.01M | $830.09M | $845.79M | $855.43M | $868.89M | $894.48M | $915.21M | $922.31M | – | – |
| Other | – | – | $17.83M | $13.46M | $8.22M | $7.09M | $6.74M | $6.55M | $6.22M | $5.97M | $5.80M | $5.58M | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hiya | -$33.49M | $1.33M | $3.41M | – | – | – | – | – | – | – | – | – | – |
| Direct selling | – | – | – | $43.32M | $57.58M | $62.67M | $70.78M | – | – | – | – | – | – |
| Other | – | – | -$6.48M | -$4.20M | -$4.72M | -$4.97M | -$4.60M | – | – | – | – | – | – |
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia Pacific total | $617.03M | $623.11M | $627.16M | $643.26M | $663.89M | $671.29M | $682.99M | $692.90M | $702.83M | $725.82M | $740.44M | $746.76M | 67.6% | -7.1% |
| Greater China | $430.57M | $429.13M | $424.54M | $437.08M | $446.77M | $449.11M | $457.98M | $461.31M | $465.66M | $478.89M | $475.10M | $477.47M | 47.1% | -3.6% |
| China | $389.88M | $386.64M | $381.82M | $393.74M | $402.40M | $405.41M | $413.47M | $416.82M | $420.22M | $432.99M | $427.27M | $429.64M | 42.7% | -3.1% |
| Americas and Europe | $296.33M | $302.83M | $298.09M | $269.41M | $235.33M | $204.95M | $171.52M | $169.08M | $172.29M | $174.63M | $180.58M | $181.12M | 32.4% | +25.9% |
| United States | $225.50M | $230.50M | $224.89M | $195.42M | $160.00M | $127.56M | $91.80M | $88.53M | $90.04M | $92.09M | $95.91M | $98.93M | 24.7% | +40.9% |
| Southeast Asia Pacific | $122.77M | $126.94M | $132.00M | $135.85M | $143.94M | $146.45M | $146.80M | $147.85M | $149.73M | $153.67M | $163.89M | $165.37M | 13.4% | -14.7% |
| North Asia | $63.69M | $67.04M | $70.63M | $70.34M | $73.19M | $75.73M | $78.21M | $83.74M | $87.44M | $93.26M | $101.45M | $103.92M | 7.0% | -13.0% |
| South Korea | – | – | $68.86M | – | – | – | $76.45M | $81.91M | $85.58M | $91.19M | $99.11M | $101.49M | – | – |
From the segment and revenue-disaggregation notes of Usana Health Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.